Particularly, four out of six patients showed an additional molecular impairment; this was mainly mediated by TP53 gene status via the occurrence of a new somatic TP53 variant in the metastatic disease sample (two cases), or via an increased VAF% in the primary tumor sample (two cases). This evidence concerns the gene TP53 and metastatic neoplasm.